Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for chronic obstructive pulmonary disorder (COPD), the companies are touting ...

AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...

Meanwhile, in a likely welcome diversion from the current attention on China, AZ reported some positive pipeline news this morning, specifically that its Amgen-partnered asthma drug Tezspire ...

AIO-001 is a long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a drug in the same class as AstraZeneca’s first-to-market Tezspire (tezepelumab), which was approved ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo WILMINGTON, DE, USA I November 08, 2024 I ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not expect the antibody to outperform Dupixent. The partners did not reveal ...

Full results from the trial will be presented at an upcoming medical meeting. Tezepelumab is currently approved under the brand name Tezspire ® for the add-on maintenance treatment of severe asthma in ...

The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs ...

Am­gen and As­traZeneca said on Fri­day that their asth­ma drug Tezspire re­duced nasal con­ges­tion and the size of nasal polyps in pa­tients with a dif­fer­ent … ...